<?xml version="1.0" encoding="UTF-8"?>
<p>What are we to do? Until a vaccine is available, combination antiviral therapy and rapid diagnostic testing may be needed (
 <xref ref-type="bibr" rid="R7">
  <italic>7</italic>
 </xref>). Given the recently described low sensitivity of currently available rapid tests, applying such assays to all patients is problematic (
 <xref ref-type="bibr" rid="R10">
  <italic>10</italic>
 </xref>). If rapid testing has a role, it should be used in testing persons at highest risk for developing influenza complications. However, early empiric therapy based on clinical manifestations and knowledge of circulating strains is likely more appropriate than reliance on tests with low sensitivity. Updated guidelines recently issued by the World Health Organization (
 <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf</ext-link>) and the Centers for Disease Control and Prevention (
 <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/h1n1flu/recommendations.htm" xmlns:xlink="http://www.w3.org/1999/xlink">www.cdc.gov/h1n1flu/recommendations.htm</ext-link>) for prophylaxis should be followed to keep resistance in check and save the lives of patients.
</p>
